Investigational drug for cardiovascular and/or chronic kidney disease

Trial ID:
IRB-24-8431
Athena Philis-Tsimikas, M.D.

Inclusion Criteria

Patients must:

  • Have a BMI 27 kg/m2 or more
  • Be 45 years of age or older
  • Have heart disease, chronic kidney disease, or both
  • Be willing to take part and follow study procedures

Exclusion Criteria

Patients must not:

  • Have Type 1 Diabetes or history of diabetic ketoacidosis
  • Have acute decompensated heart failure requiring hospitalization.
  • Have New York Heart Association (NYHA) Classification Class IV heart failure at screening
  • Have received any form of dialysis = 90 days from the date of randomization
  • Have had a kidney transplant or have a transplant procedure scheduled
  • Have had or plan to have a surgical treatment for obesity,
  • Have a history of chronic or acute pancreatitis
  • Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2
  • Have a known clinically significant gastric emptying abnormality, such as severe gastroparesis or gastric outlet obstruction

Additional Info

Participants will be randomly assigned (by chance) to receive either the investigational medicine (retatrutide) or placebo (no active medication).

The study is expected to last for about 5 years, but may continue beyond 5 years until all the information is collected. There are 27 planned study visits, and 1 final study visit. If the study lasts longer than 5 years, you will have visits every 3 months until all information is collected.

Contact Info:

  • Teresa Juarez, RN
  • juarez.teresa@scrippshealth.org
  • 858-678-7050